1. Home
  2. RGLD vs RPRX Comparison

RGLD vs RPRX Comparison

Compare RGLD & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royal Gold Inc.

RGLD

Royal Gold Inc.

HOLD

Current Price

$209.32

Market Cap

17.0B

Sector

Industrials

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$38.41

Market Cap

16.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGLD
RPRX
Founded
1981
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0B
16.2B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RGLD
RPRX
Price
$209.32
$38.41
Analyst Decision
Buy
Strong Buy
Analyst Count
8
3
Target Price
$213.38
$46.00
AVG Volume (30 Days)
726.8K
4.0M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
0.86%
2.30%
EPS Growth
66.97
N/A
EPS
7.28
1.75
Revenue
$849,255,000.00
$2,349,844,000.00
Revenue This Year
$25.73
$37.13
Revenue Next Year
$64.70
$1.48
P/E Ratio
$28.77
$21.84
Revenue Growth
28.17
3.70
52 Week Low
$130.67
$24.05
52 Week High
$209.43
$41.24

Technical Indicators

Market Signals
Indicator
RGLD
RPRX
Relative Strength Index (RSI) 66.72 46.84
Support Level $198.14 $39.24
Resistance Level $207.66 $39.88
Average True Range (ATR) 5.69 0.89
MACD 1.21 -0.24
Stochastic Oscillator 98.87 34.95

Price Performance

Historical Comparison
RGLD
RPRX

About RGLD Royal Gold Inc.

Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: